DK1618092T3 - Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere - Google Patents

Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere

Info

Publication number
DK1618092T3
DK1618092T3 DK04751133.2T DK04751133T DK1618092T3 DK 1618092 T3 DK1618092 T3 DK 1618092T3 DK 04751133 T DK04751133 T DK 04751133T DK 1618092 T3 DK1618092 T3 DK 1618092T3
Authority
DK
Denmark
Prior art keywords
aryl
kinase inhibitors
compounds useful
amide compounds
substituted pyrazole
Prior art date
Application number
DK04751133.2T
Other languages
Danish (da)
English (en)
Inventor
Alaric Dyckman
Jagabandhu Das
Katerina Leftheris
Chunjian Liu
Rulin Zhao
Bang-Chi Chen
Stephen T Wrobleski
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1618092T3 publication Critical patent/DK1618092T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK04751133.2T 2003-05-01 2004-05-03 Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere DK1618092T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46702903P 2003-05-01 2003-05-01
PCT/US2004/013604 WO2004099156A1 (en) 2003-05-01 2004-05-03 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1618092T3 true DK1618092T3 (da) 2011-01-31

Family

ID=33435012

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04751133.2T DK1618092T3 (da) 2003-05-01 2004-05-03 Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere

Country Status (27)

Country Link
US (8) US7414056B2 (enExample)
EP (5) EP2133348B1 (enExample)
JP (1) JP4601611B2 (enExample)
KR (1) KR20060022649A (enExample)
CN (1) CN1816529A (enExample)
AT (2) ATE482200T1 (enExample)
AU (1) AU2004236240C1 (enExample)
BR (1) BRPI0409949A (enExample)
CA (1) CA2524321A1 (enExample)
CO (1) CO5640039A2 (enExample)
DE (1) DE602004029242D1 (enExample)
DK (1) DK1618092T3 (enExample)
ES (3) ES2370463T3 (enExample)
GE (1) GEP20074236B (enExample)
HR (1) HRP20100670T1 (enExample)
IS (1) IS8101A (enExample)
MX (1) MXPA05011666A (enExample)
NO (1) NO20054970L (enExample)
NZ (1) NZ543375A (enExample)
PL (1) PL1618092T3 (enExample)
PT (1) PT1618092E (enExample)
RS (1) RS20050789A (enExample)
RU (1) RU2342365C2 (enExample)
SI (1) SI1618092T1 (enExample)
UA (1) UA81668C2 (enExample)
WO (3) WO2004099156A1 (enExample)
ZA (1) ZA200508830B (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
PL1618092T3 (pl) * 2003-05-01 2011-02-28 Bristol Myers Squibb Co Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
ES2360292T3 (es) * 2003-12-03 2011-06-02 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de 1,2,3-triazol amida como inhibidores de la producción de citoquinas.
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
PT1725544E (pt) * 2004-03-09 2009-07-02 Boehringer Ingelheim Pharma 3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
JP4865702B2 (ja) * 2004-05-03 2012-02-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害剤
US7485657B2 (en) * 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
CN101072758B (zh) 2004-10-12 2013-07-31 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
RU2425677C2 (ru) * 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
EP1911751A4 (en) 2005-06-21 2010-10-20 Mitsui Chemicals Agro Inc AMID DERIVATIVE AND PESTICIDE CONTAINING SUCH A COMPOUND
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007052843A1 (ja) * 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
BRPI0620362A2 (pt) * 2005-12-22 2012-07-03 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, métodos para produzir um efeito inibidor de csf-1r quinase em um animal de sangue quente, para produzir um efeito anti-cáncer em um animal de sangue quente e para tratar doença, e, composição farmacêutica
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
KR20110007258A (ko) 2006-03-22 2011-01-21 에프. 호프만-라 로슈 아게 11-베타-ｈｓｄ-1로서의 피라졸
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2675511A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
WO2008057775A2 (en) * 2006-10-27 2008-05-15 Bristol-Myers Squibb Company Heterocyclic amide compounds useful as kinase inhibitors
CN101522636A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 用作蛋白激酶抑制剂的3-氨基-吡唑-4-酰胺衍生物
CN101611024A (zh) * 2006-12-20 2009-12-23 百时美施贵宝公司 芳基-取代的吡唑-酰胺化合物的晶形
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
JP2010522770A (ja) * 2007-03-29 2010-07-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害物質
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
KR20100017372A (ko) * 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물
AU2008277783B2 (en) 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
KR20100033419A (ko) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
HRP20140047T1 (en) 2007-08-22 2014-02-14 Astrazeneca Ab Cycloptopyl amide derivatives
US8080546B2 (en) 2007-10-26 2011-12-20 Amgen Inc. Pyrazolo-pyridinone derivatives and methods of use
EP2210876B1 (en) 2007-11-01 2015-05-20 Takeda Pharmaceutical Company Limited Heterocyclic compound as glucagon antagonist
JP5465658B2 (ja) 2008-03-05 2014-04-09 武田薬品工業株式会社 複素環化合物
WO2009140342A1 (en) * 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
EP2151434A1 (en) 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
WO2010017902A1 (de) 2008-08-14 2010-02-18 Bayer Cropscience Aktiengesellschaft Insektizide 4-phenyl-1h-pyrazole
EP2184273A1 (de) * 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
WO2010071583A1 (en) * 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
CL2009001796A1 (es) * 2009-02-06 2011-09-16 Takeda Pharmaceuticals Co Compuestos derivados de heteroarilo-(benceno/heteroarilo) fusionados con actividad antagonista de glucagon; composicion farmaceutica; y su uso para suprimir la produccion de azucar y para la terapia o el tratamiento de la diabetes.
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
CN102666553B (zh) 2009-10-01 2015-05-06 赛马拜制药公司 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
CA2790040A1 (en) 2010-02-18 2011-08-25 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
KR101464060B1 (ko) 2010-04-07 2014-11-20 에프. 호프만-라 로슈 아게 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
EP2569301A1 (en) 2010-05-12 2013-03-20 Abbvie Inc. Indazole inhibitors of kinase
WO2012138809A1 (en) * 2011-04-05 2012-10-11 Dawei Zhang Heterocyclic compounds as kinase inhibitors
JP6299591B2 (ja) * 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
MX2015007051A (es) 2012-12-07 2016-01-12 Chemocentryx Inc Diazol lactamas.
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
EP2935227B1 (en) 2012-12-21 2017-09-13 ChemoCentryx, Inc. Diazole amides as ccr1 receptor antagonists
BR112015022340A2 (pt) 2013-03-15 2017-07-18 Verseon Corp método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
JP6479749B2 (ja) * 2013-03-15 2019-03-06 ヴァーセオン コーポレイション トロンビン阻害剤としてのハロゲノピラゾール
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP3076789A4 (en) * 2013-12-04 2017-11-22 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
PT3805233T (pt) 2014-01-13 2024-04-15 Aurigene Oncology Ltd Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US9815792B2 (en) 2014-04-02 2017-11-14 Bayer Cropscience Aktiengesellschaft Method for producing carboxamides
EP3140298A1 (en) * 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2015173347A1 (de) * 2014-05-14 2015-11-19 At & S Austria Technologie & Systemtechnik Aktiengesellschaft Leiterzug mit verbreiterungsfreiem übergang zwischen leiterbahn und kontaktstruktur
RU2583158C2 (ru) * 2014-06-06 2016-05-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" Метил 5-(арилкарбамоил)-1-(бензил и фенил)-4-циннамоил-1н-пиразол-3-карбоксилаты, проявляющие анальгетическую активность, и способ их получения
MX2016017147A (es) * 2014-06-20 2017-06-07 Aurigene Discovery Tech Ltd Compuestos de indazole substituidos como inhibidores de irak4.
MX2017003624A (es) 2014-09-17 2017-07-13 Verseon Corp Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
LT3261639T (lt) 2015-02-27 2022-11-25 Verseon International Corporation Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
HUE054503T2 (hu) 2015-12-16 2021-09-28 Nippon Soda Co Arilazol vegyület és kártevõ elleni szer
PL3439653T3 (pl) 2016-04-07 2021-07-05 Chemocentryx, Inc. Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
ES2816003T3 (es) 2016-09-15 2021-03-31 Boehringer Ingelheim Int Compuestos de heteroaril carboxamida como inhibidores de RIPK2
EP4212523A1 (en) * 2016-10-26 2023-07-19 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
SG11201903871TA (en) * 2016-11-03 2019-05-30 Bristol Myers Squibb Co Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CA3056893A1 (en) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
DK3691620T3 (da) 2017-10-05 2022-10-03 Fulcrum Therapeutics Inc P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
RS65572B1 (sr) 2017-10-31 2024-06-28 Curis Inc Inhibitor irak4 u kombinaciji sa inhibitorom bcl-2 za upotrebu u lečenju kancera
CN110028450A (zh) * 2018-01-12 2019-07-19 沈阳中化农药化工研发有限公司 一种吡唑酰胺类化合物的制备方法
RU2020136310A (ru) * 2018-04-06 2022-05-06 ПРАКСИС БАЙОТЕК ЭлЭлСи Ингибиторы atf6 и их применение
CN112585128B (zh) 2018-06-18 2023-02-21 詹森药业有限公司 作为malt1抑制剂的吡唑衍生物
WO2019243965A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyrazole derivatives as malt1 inhibitors
JP7482122B2 (ja) * 2018-07-03 2024-05-13 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
KR20210151880A (ko) 2019-04-11 2021-12-14 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피리딘 고리 함유 유도체
US11427558B1 (en) 2019-07-11 2022-08-30 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
WO2024226603A1 (en) * 2023-04-24 2024-10-31 Regents Of The University Of Minnesota Therapeutic compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134987A (en) * 1976-01-14 1979-01-16 Huppatz John L Compounds and compositions
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPH04316559A (ja) 1990-11-28 1992-11-06 Nissan Chem Ind Ltd ピラゾールカルボキサニリド誘導体及び殺菌剤
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
TW290529B (enExample) * 1992-12-14 1996-11-11 Asahi Glass Co Ltd
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
AUPO622597A0 (en) * 1997-04-15 1997-05-08 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
KR20010024175A (ko) * 1997-09-23 2001-03-26 돈 리사 로얄 시토킨에 의해 매개되는 질환 치료용 아미드 유도체
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
CA2331878A1 (en) 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
IL141979A0 (en) * 1998-09-25 2002-03-10 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
AU755202B2 (en) 1998-12-04 2002-12-05 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
AU2460600A (en) * 1999-02-10 2000-08-29 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
CN1281604C (zh) 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
FR2795726A1 (fr) * 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
AU1416501A (en) 1999-11-18 2001-05-30 Ajinomoto Co., Inc. Novel phenylalanine derivatives
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6194132B1 (en) * 1999-12-28 2001-02-27 Eastman Kodak Company Photographic element, compound, and process
US6197492B1 (en) * 1999-12-28 2001-03-06 Eastman Kodak Company Photographic element, compound, and process
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
IL153645A0 (en) * 2000-07-31 2003-07-06 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11cby receptor
WO2002023986A1 (en) * 2000-08-25 2002-03-28 Sankyo Company, Limited 4-acylaminopyrazole derivatives
AU9578901A (en) 2000-10-30 2002-05-15 Kudos Pharm Ltd Phthalazinone derivatives
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
MXPA03009847A (es) * 2001-04-27 2004-02-12 Vertex Pharma Inhibidores de cinasa derivados de pirazol.
CA2446756C (en) 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
EP1406875B1 (en) * 2001-06-26 2013-07-31 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
US6916813B2 (en) * 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
US6521395B1 (en) * 2002-01-30 2003-02-18 Eastman Kodak Company Infrared couplers for incorporating and recovering metadata
TW200302726A (en) 2002-01-31 2003-08-16 Ono Pharmaceutical Co Nitrogen-containing bicyclic compound and medicament containing same as active ingredient
WO2004011440A1 (ja) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
WO2004035545A2 (en) 2002-10-18 2004-04-29 E.I. Du Pont De Nemours And Company Azolecarboxamide herbicides
EP1583746A1 (en) * 2003-01-06 2005-10-12 Eli Lilly And Company A pyrazole derivative as ppar modulator
ATE479667T1 (de) 2003-02-06 2010-09-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
PL1618092T3 (pl) * 2003-05-01 2011-02-28 Bristol Myers Squibb Co Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy
WO2004106324A1 (en) 2003-05-27 2004-12-09 E.I. Dupont De Nemours And Company Azolecarboxamide herbicides
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0329572D0 (en) 2003-12-20 2004-01-28 Astrazeneca Ab Amide derivatives
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US20060069132A1 (en) 2004-04-07 2006-03-30 Armel Gregory R Azolecarboxamide herbicides
US20080312215A1 (en) 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
RU2005135162A (ru) 2006-05-10
US20050004176A1 (en) 2005-01-06
EP1617840A4 (en) 2008-08-20
EP1618092B1 (en) 2010-09-22
EP1620108A4 (en) 2008-08-27
DE602004029242D1 (en) 2010-11-04
EP2133348A1 (en) 2009-12-16
WO2004098528A3 (en) 2005-07-14
WO2004099156A1 (en) 2004-11-18
US7151113B2 (en) 2006-12-19
JP4601611B2 (ja) 2010-12-22
RS20050789A (sr) 2008-04-04
NZ543375A (en) 2009-05-31
US7396935B2 (en) 2008-07-08
WO2004098518A2 (en) 2004-11-18
US20050159424A1 (en) 2005-07-21
ZA200508830B (en) 2009-05-27
US20060247247A1 (en) 2006-11-02
RU2342365C2 (ru) 2008-12-27
WO2004098528A2 (en) 2004-11-18
KR20060022649A (ko) 2006-03-10
EP1618092A1 (en) 2006-01-25
US20100016320A1 (en) 2010-01-21
US7592338B2 (en) 2009-09-22
EP1618092A4 (en) 2008-08-20
PL1618092T3 (pl) 2011-02-28
CO5640039A2 (es) 2006-05-31
US7390810B2 (en) 2008-06-24
US20040248853A1 (en) 2004-12-09
BRPI0409949A (pt) 2006-04-25
ES2386784T3 (es) 2012-08-30
EP1620108A2 (en) 2006-02-01
EP2385041B1 (en) 2013-09-18
US7605273B2 (en) 2009-10-20
WO2004098518A3 (en) 2005-01-27
CN1816529A (zh) 2006-08-09
MXPA05011666A (es) 2005-12-15
EP2133348B1 (en) 2011-08-31
EP1620108B1 (en) 2012-06-06
EP1617840A2 (en) 2006-01-25
US20080004278A1 (en) 2008-01-03
PT1618092E (pt) 2010-11-22
US7414056B2 (en) 2008-08-19
NO20054970L (no) 2006-01-11
ES2350837T3 (es) 2011-01-27
ATE522525T1 (de) 2011-09-15
UA81668C2 (en) 2008-01-25
CA2524321A1 (en) 2004-11-18
ES2370463T3 (es) 2011-12-16
IS8101A (is) 2005-10-28
AU2004236240A1 (en) 2004-11-18
AU2004236240B2 (en) 2010-06-17
AU2004236240C1 (en) 2010-11-04
EP2385041A1 (en) 2011-11-09
GEP20074236B (en) 2007-11-12
HRP20100670T1 (hr) 2011-01-31
SI1618092T1 (sl) 2010-11-30
NO20054970D0 (no) 2005-10-26
ATE482200T1 (de) 2010-10-15
US20080108626A1 (en) 2008-05-08
JP2006525359A (ja) 2006-11-09
US20080275092A1 (en) 2008-11-06
US7253170B2 (en) 2007-08-07

Similar Documents

Publication Publication Date Title
DK1618092T3 (da) Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
WO2004071440A3 (en) Thiazolyl-based compounds useful as kinase inhibitors
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2006062984A3 (en) Inhibitors of protein kinases
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20044807L (no) Heratitt C virus inhibitorer
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
GB0100889D0 (en) Compounds
NO20062267L (no) Hepatitt C virus inhibitorer
NO20062339L (no) Hepatitt C virus-inhibitoerer
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
GB0129476D0 (en) Organic compounds
WO2006062982A3 (en) Urea inhibitors of map kinases
DE60324544D1 (de) Muskarin antagonisten
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
ATE315550T1 (de) Fungizide phenylamidinderivative
UA83710C2 (ru) Смесь и семена, которые ее содержат, композиция, способ борьбы с фитопатогенными грибами, вредными насекомыми, паукообразными или нематодами
DE60108089D1 (de) Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel
DE60105618D1 (de) Dihydroporphyrinderivate und ihre verwendung
MY141784A (en) Phenylpyridylpiperazine compounds
DE60108209D1 (de) Fungizide Phenylimidate-Derivate
TW200600013A (en) 5,6-Dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds
MY140963A (en) Phenylpyridylpiperazine compounds